The human health therapeutics research centre in Royalmount has a pilot plant facility and has had that facility for many years. We can produce a vaccine product, but it requires a good manufacturing practices approval, Health Canada approval, for the facility. In the case of a specific vaccine candidate, it would have required an emergency authorization for the production of that candidate for human use.
In the case of the commitments and the statements made—the pilot-production level of production, which is the 200,000 doses—it was certainly the goal of the NRC to put in place the necessary procedures, processes and changes in our facility in order to accomplish that. Of course, we were targeting an international vaccine candidate. It's well known. It did not come into the facility. Therefore, without the product, you can't produce.
The facility is capable of a level of production that is in line with what's been said, but of course, by the time we reached the fall, we were dealing with a scenario where we had approved vaccines coming online. We had them starting to be distributed in December in Canada from approved vaccines that had, of course, advanced very rapidly internationally and that Canada, of course, had acquired—